References
- [Cited 2017 Dec 12]. Available from: http://www.who.int/mediacentre/factsheets/fs104/en/.
- http://www.who.int/tb/post2015_strategy/en/.
- Horsburgh CR, Barry CE, Lange C. Treatment of tuberculosis. Longo DL, editor. N Engl J Med [Internet]. 2015 373:2149–2160. [cited 2016 Jun 17. Available from: http://www.nejm.org/doi/10.1056/NEJMra1413919.
- Jindani A, Doré CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med [Internet]. 2003 [cited 2016 Jun 24];167:1348–1354. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12519740.
- Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis – advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis [Internet]. 2016;16:e34–e46. Available from: http://www.sciencedirect.com/science/article/pii/S1473309916000700.
- Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet (London, England) [Internet]. 2010 [cited 2016 Jun 17];375:2100–2109. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20488518.
- Magis-Escurra C, van den Boogaard J, Ijdema D, et al. Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther [Internet]. 2012 [cited 2016 Jun 18];25:83–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22179055.
- Babalik A, Babalik A, Mannix S, et al. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J [Internet]. [cited 2016 Jun 24];18:225–229. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22059181.
- Egelund EF, Alsultan A, Peloquin CA. Optimizing the clinical pharmacology of tuberculosis medications. Clin Pharmacol Ther [Internet]. 2015 [cited 2016 Feb 26];98:387–393. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26138226.
- Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis [Internet]. 2013; 13:27–35. [cited 2016 Jun 21]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23103177.
- WHO Treatment guidelines for drug-resistant tuberculosis, 2016 Update - PubMed - NCBI [Internet]. [cited 2017 Jan 22]. Available from: https://www-ncbi-nlm-nih-gov.offcampus.dam.unito.it/pubmed/27748093.
- [Cited 2017 Dec 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02342886?term=pa-824+moxifloxacin&rank=2
- TB Alliance. NC-005 trial [Internet]. [Cited 2017 Dec 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02193776?term=bedaquiline&rank=8.
- Conradie F, Diacon Andreas H, Daniel E, et al., THE NIX-TB TRIAL OF PRETOMANID, BEDAQUILINE AND LINEZOLID TO TREAT XDR-TB. 2017. [Cited 2017 Dec 13]. Available from: http://www.croiconference.org/sessions/nix-tb-trial-pretomanid-bedaquiline-and-linezolid-treat-xdr-tb.
- WHO. The World Health Organization. Treatment of tuberculosis: guidelines [Internet]. 4th ed. 2010;160. [Cited 2017 Dec 13]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK138741/#ch2.s3.
- Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1468–1481.
- Chigutsa E, Pasipanodya JG, Visser ME, et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother [Internet]. 2015 [cited 2016 Jun 9];59:38–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25313213.
- Reynolds J, Heysell SK. Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol [Internet]. 2014 [cited 2016 Jun 17];10:813–823. Available from: http://www.tandfonline.com/doi/full/10.1517/17425255.2014.895813.
- Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother [Internet]. 2007 [cited 2016 Jun 24];51:3781–3788. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17724157.
- Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother [Internet]. 2003 [cited 2016 Jun 24];47:2118–2124. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12821456.
- Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med [Internet]. 2001 [cited 2016 Jun 24];1:2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11737875.
- Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis [Internet]. 2013 [cited 2016 Jun 17];208:1464–1473. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23901086.
- Burhan E, Ruesen C, Ruslami R, et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother [Internet]. 2013 [cited 2016 Jun 21];57:3614–3619. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23689725.
- Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis [Internet]. 2009 [cited 2016 Jun 21];48:1685–1694. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19432554.
- Prahl JB, Johansen IS, Cohen AS, et al. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J Antimicrob Chemother [Internet]. 2014 [cited 2016 Jun 24];69:2841–2847. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25140577.
- Srivastava S, Sherman C, Meek C, et al. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob Agents Chemother [Internet]. 2011 [cited 2016 Jun 24];55:5085–5089. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21896907.
- Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs [Internet]. 2002 [cited 2016 Jun 24];62:2169–2183. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12381217.
- Babalik A, Ulus IH, Bakirci N, et al. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. Antimicrob Agents Chemother [Internet]. 2013 [cited 2016 Jun 24];57:5740–5742. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23979746.
- McIlleron H, Wash P, Burger A, et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother [Internet] 2006 [cited 2016 Jun 24];50:1170–1177. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16569826.
- Heysell SK, Moore JL, Keller SJ, et al. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis [Internet]. 2010 [cited 2016 Jun 24];16:1546–1553. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20875279.
- Calcagno A, Motta I, Milia MG, et al. Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi. Br J Clin Pharmacol [Internet]. 2015 [cited 2016 Feb 26];79:801–808. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25377591.
- Allanson AL, Cotton MM, Tettey JNA, et al. Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring. J Pharm Biomed Anal [Internet]. 2007 [cited 2017 Jan 11];44:963–969. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0731708507002312.
- Lee K, Jun S-H, Han M, et al. Multiplex assay of second-line anti-tuberculosis drugs in dried blood spots using ultra-performance liquid chromatography-tandem mass spectrometry. Ann Lab Med [Internet]. 2016 [cited 2017 Jan 23];36:489. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27374716.
- Vu DH, Alffenaar JWC, Edelbroek PM, et al. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des [Internet]. 2011 [cited 2017 Jan 29];17:2931–2939. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21834763.
- Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs [Internet]. 2014 [cited 2016 Jun 24];74:839–854. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24846578.
- Sturkenboom MGG, Mulder LW, De Jager A, et al. Pharmacokinetic modeling and optimal sampling strategies for therapeutic drug monitoring of rifampin in patients with tuberculosis. Antimicrob Agents Chemother [Internet]. 2015 [cited 2016 Apr 11];59:4907–4913. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4505200&tool=pmcentrez&rendertype=abstract.
- Alsultan A, An G, Peloquin CA. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis. Antimicrob Agents Chemother [Internet]. 2015 [cited 2016 May 18];59:3800–3807. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4468713&tool=pmcentrez&rendertype=abstract.
- Dijkstra JA, van Altena R, Akkerman OW, et al. Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. Int J Antimicrob Agents [Internet]. 2015 [cited 2016 May 29];46:332–337. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26228464.
- World Health Organization (WHO). Global Tuberculosis Report 2016 [Internet]. [cited 2017 Apr 17]. Available from: http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1.
- Rockwood N, Du Bruyn E, Morris T, et al. Assessment of treatment response in tuberculosis. Expert Rev Respir Med [Internet]. 2016 [cited 2016 May 18];10:643–654. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27030924.
- Heemskerk AD, Bang ND, Mai NTH, et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med [Internet]. 2016 [cited 2016 Jun 24];374:124–134. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26760084.
- Boeree MJ, Gillespie SH, Hoelscher M, et al. Therapy for tuberculous meningitis. N Engl J Med [Internet]. 2016 [cited 2016 Jun 24];374:2187–2188. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27248636.
- Peloquin CA, Namdar R, Singleton MD, et al. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest [Internet]. 1999 [cited 2017 Jan 29];115:12–18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9925057.
- van Ingen J, Aarnoutse RE, Donald PR, et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis [Internet]. 2011 [cited 2016 Jun 8];52:e194–e199. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21467012.
- Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med [Internet]. 2015 [cited 2016 Jun 21];191:1058–1065. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25654354.
- Milstein M, Lecca L, Peloquin C, et al. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis [Internet]. 2016 [cited 2016 Sep 3];16:453. Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1790-x.
- Boeree M, Hoelscher M. High-dose rifampin, SQ109 and moxifloxacin for treating TB: the PanACEA MAMS-TB trial. Presented at the Conference on Retroviruses and Opportunistic Infections 2015 Feb 25; Seattle. abstract. No Title.
- Mehta JB, Shantaveerapa H, Byrd RP, et al. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest [Internet]. 2001 [cited 2016 Jun 18];120:1520–1524. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11713129.
- Te Brake L, Dian S, Ganiem AR, et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents [Internet]. 2015 [cited 2016 Jun 24];45:496–503. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25703312.
- Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother [Internet]. 2007 [cited 2016 Jun 8];51:2994–2996. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17517849.
- Chirehwa MT, Rustomjee R, Mthiyane T, et al. Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction. Antimicrob Agents Chemother [Internet]. 2016 [cited 2016 Jun 18];60:487–494. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26552972.
- Smythe W, Khandelwal A, Merle C, et al. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents Chemother [Internet]. 2012 [cited 2016 May 30];56:2091–2098. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3318330&tool=pmcentrez&rendertype=abstract.
- Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet [Internet]. 2003 [cited 2017 Jan 29];42:819–850. Available from: http://link.springer.com/10.2165/00003088-200342090-00003.
- Yapa HM, Boffito M, Pozniak A Critical review: what dose of rifabutin is recommended with antiretroviral therapy? J Acquir Immune Defic Syndr [Internet]. 2016 [cited 2016 Jun 8];72:138–152. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26855245.
- Blaschke TF, Skinner MH The clinical pharmacokinetics of rifabutin [with discussion]. Source Clin Infect Dis [Internet]. 1996 [cited 2017 Apr 15];22:15–22. Available from: http://www.jstor.org/stable/4459386.
- Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet (London, England) [Internet]. 1999 [cited 2017 Jan 22];353:1843–1847. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10359410.
- Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med [Internet]. 2003 [cited 2016 Jun 21];167:1341–1347. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12531776.
- Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med [Internet]. 2014 [cited 2016 Jun 21];371:1599–1608. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25337749.
- Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med [Internet]. 2011 [cited 2017 Jan 22];365:2155–2166. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1104875.
- Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis [Internet]. 2012 [cited 2017 Jan 22];206:1030–1040. Available from: http://jid.oxfordjournals.org/lookup/doi/10.1093/infdis/jis461.
- Dorman SE, Savic RM, Goldberg S, et al. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med [Internet]. 2015 [cited 2017 Apr 10];191:333–343. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25489785.
- Savic RM, Lu Y, Bliven-Sizemore E, et al. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother [Internet]. 2014 [cited 2017 Jan 22];58:3035–3042. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24614383.
- Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med [Internet]. 2004 [cited 2017 Jan 22];169:1191–1197. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14962821.
- Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis [Internet]. 2016 [cited 2016 Sep 3]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27516382.
- Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet (London, England) [Internet]. 2002 [cited 2017 Jan 17];360:528–534. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12241657.
- Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol Microbiol [Internet]. 2006 [cited 2017 Jan 22];62:1220–1227. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17074073.
- Zhang Y, Young D. Molecular genetics of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother [Internet]. 1994 [cited 2017 Jan 29];34:313–319. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7829406.
- Donald PR, Sirgel FA, Botha FJ, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med [Internet]. 1997 [cited 2016 Jun 24];156:895–900. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9310010.
- Victor TC, Warren R, Butt JL, et al. Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis. J Med Microbiol [Internet]. 1997 [cited 2017 Apr 13];46:847–857. Available from: http://jmm.microbiologyresearch.org/content/journal/jmm/10.1099/00222615-46-10-847.
- Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science [Internet]. 1994 [cited 2017 Apr 13];263:227–230. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8284673.
- Moulding TS. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am Rev Respir Dis [Internet]. 1981 [cited 2017 Apr 13];123:262–264. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6784621.
- Schaaf HS, Victor TC, Engelke E, et al. Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur J Clin Microbiol Infect Dis [Internet]. 2007 [cited 2017 Apr 13];26:203–205. Available from: http://link.springer.com/10.1007/s10096-007-0257-9.
- Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis [Internet]. 2008 [cited 2017 Apr 13];12:139–145. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18230245.
- Wallace RJGDE. Antimycobacterial agents. Mandell GL, Bennett JE, Dolin R, eds. Mand. Douglas, Bennett’s princ. pract. infect. dis. 6th ed. New York. Elsevier. 2005. p. 489–499.
- Lacroix C, Guyonnaud C, Chaou M, et al. Interaction between allopurinol and pyrazinamide. Eur Respir J [Internet]. 1988 [cited 2017 Jan 29];1:807–811. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3229478.
- Lanoix J-P, Tasneen R, O’Brien P, et al. High systemic exposure of pyrazinoic acid has limited anti-tuberculosis activity in murine and rabbit models of tuberculosis. Antimicrob Agents Chemother [Internet]. 2016 [cited 2016 May 18]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27139472.
- Mitchison DA, Fourie PB. The near future: improving the activity of rifamycins and pyrazinamide. Tuberculosis (Edinb). [Internet]. 2010 [cited 2016 Jun 24];90:177–181. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20382083.
- Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (pa-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul. Lancet (London, England). 2015 May 2:1738–1747.
- Whitfield MG, Soeters HM, Warren RM, et al. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. Mokrousov I, editor. PLoS One [Internet]. 2015 [cited 2017 Apr 13];10:e0133869. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26218737.
- Simons SO, van der Laan T, Mulder A, et al. Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm. Clin Microbiol Infect [Internet]. 2014 [cited 2017 Apr 13];20:1015–1020. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24890253.
- Conti V, Corbi G, Simeon V, et al. Aging-related changes in oxidative stress response of human endothelial cells. Aging Clin Exp Res [Internet]. 2015 [cited 2016 Apr 8];27:547–553. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25835220.
- Mikusová K, Slayden RA, Besra GS, et al. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother [Internet]. 1995 [cited 2017 Jan 22];39:2484–2489. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8585730.
- Zhu M, Burman WJ, Starke JR, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis [Internet]. 2004 [cited 2017 Jan 29];8:1360–1367. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15581206.
- Implementing tuberculosis diagnostics: a policy framework (WHO/HTM/TB/2015.11) [Internet]. IGeneva, World Heal. Organ. 2015. [Cited 2017 Dec 13]. Available from http://apps.who.int/iris/bitstream/10665/162712/1/9789241508612_eng.pdf.
- Mandell GL, Bennett JE, Dolin R, eds. Mandell. Douglas, Bennett’s princ. pract. infect. dis. 7th ed. New York. 2009.
- Chiang C-Y, Van Deun A, Rieder HL Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis [Internet]. 2016 [cited 2017 Nov 26];20:1143–1147. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27510237.
- Fish DN Levofloxacin: update and perspectives on one of the original “respiratory quinolones”. Expert Rev Anti Infect Ther [Internet]. 2003 [cited 2017 Jan 24];1:371–387. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15482135.
- Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med [Internet]. 2014 [cited 2016 Jun 21];371:1577–1587. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25196020.
- Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med [Internet]. 2014 [cited 2016 Jun 21];371:1588–1598. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25337748.
- Weiner M, Burman W, Luo -C-C, et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother [Internet]. 2007 [cited 2017 Jan 24];51:2861–2866. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17517835.
- Nijland HMJ, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis [Internet] 2007 [cited 2017 Jan 24];45:1001–1007. Available from: http://cid.oxfordjournals.org/lookup/doi/10.1086/521894.
- Fillion A, Aubry A, Brossier F, et al. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob Agents Chemother [Internet]. 2013 [cited 2016 Jun 24];57:4496–4500. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23836169.
- Heysell SK, Pholwat S, Mpagama SG, et al. Sensititre MycoTB Plate Compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs. Antimicrob Agents Chemother [Internet]. 2015 [cited 2017 Apr 14];59:7104–7108. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26303804.
- Baietto L, Corcione S, Pacini G, et al. A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? Curr Drug Metab [Internet]. 2014 [cited 2016 Jun 6];15:581–598. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4435065&tool=pmcentrez&rendertype=abstract.
- Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med [Internet]. 2008 [cited 2016 Jun 18];178:1180–1185. Available from: http://www.atsjournals.org/doi/abs/10.1164/rccm.200806-892OC.
- Alffenaar J-WC, Kosterink JGW, Van Altena R, et al. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit [Internet]. 2010 [cited 2017 Apr 17];32:97–101. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00007691-201002000-00015.
- Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy [Internet]. 2007 [cited 2017 Jan 30];27:476–479. Available from: http://doi.wiley.com/10.1592/phco.27.3.476.
- Ashizawa N, Tsuji Y, Kawago K, et al. Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring. J Infect Chemother [Internet]. 2016 [cited 2016 Jun 28];22:331–334. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26732509.
- Moodley R, Godec TR, STREAM Trial Team. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev [Internet]. 2016 [cited 2017 Apr 14];25:29–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26929418.
- Nix DE, Adam RD, Auclair B, et al. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis [Internet]. 2004 [cited 2017 Apr 17];84:365–373. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15525560.
- Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother [Internet]. 2008 [cited 2016 Jun 18];52:2831–2835. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18505852.
- Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother [Internet]. 2007 [cited 2017 Jan 29];51:1011–1015. Available from: http://aac.asm.org/cgi/doi/10.1128/AAC.00898-06.
- Veziris N, Ibrahim M, Lounis N, et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med [Internet]. 2009 [cited 2017 Jan 29];179:75–79. Available from: http://www.atsjournals.org/doi/abs/10.1164/rccm.200711-1736OC.
- Svensson EM, Murray S, Karlsson MO, et al. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother [Internet]. 2014 [cited 2017 Jan 28];70:1106–1114. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25535219.
- Yang F, Bian C, Zhu L, et al. Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. J Struct Biol [Internet]. 2007 [cited 2017 Nov 26];157:348–355. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17067818.
- Szumowski JD, Lynch JB. Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Devel Ther [Internet]. 2015 [cited 2016 Jun 18];9:677–682. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25678771.
- The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. World Health Organization.WHO 2014.
- Lachâtre M, Rioux C, Le DD, et al. Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis [Internet]. 2016 [cited 2017 Jan 29];16:294. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1473309916000475.
- Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline: TABLE 1. Eur Respir J [Internet]. 2016 [cited 2017 Jan 29];48:935–938. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27288039.
- Ahmad Z, Peloquin CA, Singh RP, et al. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother [Internet]. 2011 [cited 2016 Jun 18];55:239–245. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20937781.
- Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet (London, England) [Internet]. 2012 [cited 2017 Jan 29];380:986–993. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673612610800.
- Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med [Internet]. 2003 [cited 2016 Jun 21];167:1472–1477. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12569078.
- Long MW, Snider DE, Farer LSUS. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis [Internet]. 1979 [cited 2016 Jun 24];119:879–894. Available from: http://www.ncbi.nlm.nih.gov/pubmed/110184.
- Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet [Internet]. 2001 [cited 2016 Jun 24];40:327–341. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11432536.
- Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med [Internet]. 2006 [cited 2016 Jun 8];174:935–952. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17021358.
- Poole G, Stradling P, Worlledge S. Potentially serious side effects of high-dose twice-weekly rifampicin. Br Med J [Internet]. 1971 [cited 2016 Jun 8];3:343–347. Available from: http://www.ncbi.nlm.nih.gov/pubmed/5314737.
- Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis [Internet]. 2004 [cited 2016 Jun 24];38:1538–1544. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15156439.
- De Jager P, Van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis [Internet]. 2002 [cited 2017 Apr 14];6:622–627. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12102302.
- van Altena R, Dijkstra JA, van der Meer ME, et al. Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis. Antimicrob Agents Chemother [Internet]. 2017 [cited 2017 Apr 14];61:e01400–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28069654.
- Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med [Internet]. 2003 [cited 2017 Apr 14];114:194–198. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12637133.
- Kranzer K, Elamin WF, Cox H, et al. A systematic review and meta-analysis of the efficacy and safety of N -acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB. Thorax [Internet] 2015 [cited 2017 Apr 14];70:1070–1077. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26347391.
- Sha S-H, Qiu J-H, Schacht J. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med [Internet]. 2006 [cited 2017 Apr 14];354:1856–1857. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMc053428.
- Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother [Internet]. 2002 [cited 2017 Apr 17];49:593–596. Available from: https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/49.4.593.
- Worley MV, Estrada SJ, Estrada SJ. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacother [Internet] 2014 [cited 2016 Jun 22];34:1187–1197. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25203970.
- Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis [Internet]. [cited 2016 Jun 21];5 Suppl 3: S440–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6356277.
- Patel AM, McKeon J. Avoidance and management of adverse reactions to antituberculosis drugs. Drug Saf [Internet]. 1995 [cited 2016 Jun 21];12:1–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7741981.
- Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 2011;55:4122–4127.
- Zhang W, He Y-J, Gan Z, et al. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin Exp Pharmacol Physiol [Internet] 2007 [cited 2016 Jun 19];34:1240–1244. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17973861.
- Li L-M, Chen L, Deng G-H, et al. SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury. Mol Med Rep [Internet]. 2012 [cited 2016 Jun 19];6:75–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22562052.
- Weiner M, Peloquin C, Burman W, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother [Internet]. 2010 [cited 2016 Jun 19];54:4192–4200. Available from: http://aac.asm.org/cgi/doi/10.1128/AAC.00353-10.
- Hennig S, Naiker S, Reddy T, et al. Effect of SLCO1B1 polymorphisms on rifabutin pharmacokinetics in African HIV-infected patients with tuberculosis. Antimicrob Agents Chemother [Internet]. 2016 [cited 2016 Jun 19];60:617–620. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26482301.
- Song SH, Chang HE, Jun SH, et al. Relationship between CES2 genetic variations and rifampicin metabolism. J Antimicrob Chemother [Internet]. 2013 [cited 2016 Jun 24];68:1281–1284. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23471941.
- Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol [Internet]. [cited 2016 Jun 22];25:231–259. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16815813.
- Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol [Internet]. 2013 [cited 2016 Jun 17];69:1091–1101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23150149.
- Fatiguso G, Allegra S, Calcagno A, et al. Ethambutol plasma and intracellular pharmacokinetics: a pharmacogenetic study. Int J Pharm [Internet]. 2016 [cited 2016 Jun 21];497:287–292. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26642947.
- Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochondrial 1555A→G mutation in European children. N Engl J Med [Internet]. 2009 [cited 2017 Apr 14];360:640–642. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMc0806396.
- Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol [Internet]. 2008 [cited 2016 Jun 22];23:192–202. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17995946.
- Ramachandran G, Swaminathan S. Role of pharmacogenomics in the treatment of tuberculosis: a review. Pharmgenomics Pers Med [Internet]. 2012 [cited 2016 Jun 8];5:89–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23226065.
- Lee S-W, Chung LS-C, Huang -H-H, et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis [Internet]. 2010 [cited 2016 Jun 24];14:622–626. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20392357.
- Gupta VH, Singh M, Amarapurkar DN, et al. Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population. Ann Hepatol [Internet]. [cited 2016 Jun 22];12:959–965. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24114827.
- Mukherjee A, Velpandian T, Singla M, et al. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. BMC Infect Dis [Internet]. 2015 [cited 2016 Feb 26];15:126. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4373095&tool=pmcentrez&rendertype=abstract.
- Hiruy H, Rogers Z, Mbowane C, et al. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J Antimicrob Chemother [Internet]. 2015 [cited 2016 Jun 27];70:1115–1123. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25505005.
- Swaminathan S, Pasipanodya JG, Ramachandran G, et al. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: Bread Crumb Trails in Random Forests. Clin Infect Dis [Internet]. 2016 [cited 2017 Apr 17];63:S63–S74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27742636.
- PrayGod G, Range N, Faurholt-Jepsen D, et al. Predictors of body composition changes during tuberculosis treatment in Mwanza, Tanzania. Eur J Clin Nutr [Internet]. 2015 [cited 2017 Apr 14];69:1125–1132. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25828630.
- Esposito S, D’Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J [Internet]. 2014 44:811–815. Available from: 10.1183/09031936.00060414.
- Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis [Internet]. 2010 [cited 2016 Jun 24];50:1288–1299. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20353364.
- Narendran G, Menon PA, Venkatesan P, et al. Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. Clin Infect Dis [Internet]. 2014 [cited 2016 Jun 24];59:1798–1804. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25156114.
- Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother [Internet]. 2004 [cited 2016 Jun 24];48:4473–4475. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15504887.
- van Oosterhout JJ, Dzinjalamala FK, Dimba A, et al. Pharmacokinetics of antituberculosis drugs in HIV-positive and HIV-negative adults in Malawi. Antimicrob Agents Chemother [Internet]. 2015 [cited 2016 Jun 24];59:6175–6180. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26248378.
- Taburet A-M, Sauvageon H, Grinsztejn B, et al. Pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antitubercular therapy. Clin Infect Dis [Internet]. 2015 [cited 2017 Jan 28];61:1328–1335. Available from: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/civ477.
- Ngaimisi E, Mugusi S, Minzi O, et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther [Internet]. 2011 [cited 2017 Jan 28];90:406–413. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21814190.
- Dickinson L, Winston A, Boffito M, et al. Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. J Antimicrob Chemother [Internet]. 2016 [cited 2017 Jan 30];71:1041–1045. Available from: https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkv439.
- Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis [Internet]. 2009 [cited 2017 Jan 30];48:1471–1474. Available from: https://academic.oup.com/cid/article-lookup/doi/10.1086/598336.
- Weiner M, Egelund EF, Engle M, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother [Internet]. 2014 [cited 2017 Jan 29];69:1079–1085. Available from: https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkt483.
- Pandie M, Wiesner L, McIlleron H, et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother [Internet]. 2016 [cited 2017 Jan 29];71:1037–1040. Available from: https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkv447.
- Nijland HMJ, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis [Internet]. 2006 [cited 2016 Jun 22];43:848–854. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16941365.
- Ruslami R, Nijland HMJ, Adhiarta IGN, et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother [Internet]. 2010 [cited 2016 Jun 24];54:1068–1074. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20038625.
- Requena-Méndez A, Davies G, Ardrey A, et al. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother [Internet]. 2012 [cited 2016 Jun 24];56:2357–2363. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22330931.
- Alkabab Y, Keller S, Dodge D, et al. Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. BMC Infect Dis [Internet]. 2017 [cited 2017 Apr 10];17:125. Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2226-y.
- Kjellsson MC, Via LE, Goh A, et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother [Internet]. 2012 [cited 2016 Jun 8];56:446–457. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21986820.
- Prideaux B, Dartois V, Staab D, et al. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem [Internet]. 2011 [cited 2016 May 30];83:2112–2118. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3158846&tool=pmcentrez&rendertype=abstract.
- Prideaux B, Via LE, Zimmerman MD, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med [Internet]. 2015;21:1223–1227. Available from: 10.1038/nm.3937.
- Iacobino A, Piccaro G, Giannoni F, et al. Activity of drugs against dormant Mycobacterium tuberculosis. Int J Mycobacteriology [Internet]. 2016 [cited 2017 Jan 24];5:S94–S95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28043638.
- Hartkoorn RC, Chandler B, Owen A, et al. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis (Edinb). [Internet]. 2007 [cited 2016 Jun 24];87:248–255. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17258938.
- Dhillon J, Mitchison DA Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254. Antimicrob Agents Chemother [Internet]. 1989 [cited 2017 Jan 31];33:1255–1259. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2802553.
- Hand WL, Corwin RW, Steinberg TH, et al. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis [Internet] 1984 [cited 2016 Jun 24];129:933–937. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6732052.
- Dartois V The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol [Internet]. 2014;12:159–167. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24487820.
- Baietto L, Calcagno A, Motta I, et al. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. J Antimicrob Chemother [Internet]. 2015 [cited 2016 Feb 26];70:2572–2575. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26066583.
- Hartkoorn RC, Khoo S, Back DJ, et al. A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. J Chromatogr B Analyt Technol Biomed Life Sci [Internet]. 2007 [cited 2016 Jun 24];857:76–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17643357.
- Motta I, Calcagno A, Baietto L, et al. Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. Br J Clin Pharmacol [Internet]. 2017 [cited 2017 Jan 29]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/28097677.
- Sarathy JP, Lee E, Dartois V Polyamines inhibit porin-mediated fluoroquinolone uptake in mycobacteria. PLoS One [Internet]. 2013 [cited 2016 Dec 19];8:e65806. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23755283.
- Wallis RS, Vinhas SA, Johnson JL, et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis [Internet]. 2003 [cited 2017 Jan 29];187:270–278. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12552451.
- Heysell SK, Mtabho C, Mpagama S, et al. Plasma drug activity assay for treatment optimization in tuberculosis patients. Antimicrob Agents Chemother [Internet]. 2011 [cited 2017 Apr 14];55:5819–5825. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21968363.
- Holdiness MR Clinical pharmacokinetics of clofazimine. Review Clin Pharmacokinet [Internet]. 1989 [cited 2017 Jan 31];16:74–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2656045.
- Early termination of a pk study between dolutegravir and weekly isoniazid/Rifapentine | CROI Conference [Internet]. [cited 2017 Apr 19]. Available from: http://www.croiconference.org/sessions/early-termination-pk-study-between-dolutegravir-and-weekly-isoniazidrifapentine.
- Liverpool HIV Interactions [Internet]. [cited 2017 Apr 18]. Available from: http://www.hiv-druginteractions.org/.